Hence, blocking Cdkn2a-mediated BECN1 activity holds therapeutic potential to sustain beige adipocytes in treating obesity and related metabolic diseases. The gene discussed is CDKN2A; the disease is obesity due to melanocortin 4 receptor deficiency.